The COVID-19 pandemic has emphasised the need for a coordinated pan-European response to health emergencies. On Tuesday, 19 September, AmCham EU hosted a Plenary meeting to address the future of the European Health Emergency Preparedness and Response Authority (HERA) and the lessons that can be learned from the American Biomedical Advanced Research and Development Authority (BARDA).
HERA: what is the future of the European pandemic preparedness response?
The COVID-19 pandemic has emphasised the need for a coordinated pan-European response to health emergencies. On Tuesday, 19 September, AmCham EU hosted a Plenary meeting to address the future of the European Health Emergency Preparedness and Response Authority (HERA) and the lessons that can be learned from the American Biomedical Advanced Research and Development Authority (BARDA).
The event kicked off with a panel on advancing transatlantic coordination in pandemic preparedness moderated by Emilia Valbum (3M), Vice-Chair, Healthcare Committee, AmCham EU. The conversation featured experts from Europe and the US including Tamara Weinger-Požar, Deputy Ambassador to the Permanent Representation of Slovenia; Karel Lannoo, Chief Executive, CEPS and Christopher Houchens, Director, Division of CBRN Countermeasures, BARDA. The panel centred around the need for an ambitious plan for HERA, the necessity to support research and development (R&D) as well as the role of industry.
It was followed by a keynote address delivered by Pierre Delsaux, Deputy Director-General, Directorate-General for Health and Food Safety, European Commission. Mr Delsaux highlighted that HERA will look beyond institutions and old governance models and focus on ensuring further support for R&D.
A link between HERA and BREDA will also be crucial to pandemic preparedness.With a need for better access to data, support from and to the industry as well as allocated funding, HERA can prove a valuable solution to the future of pandemic preparedness if it manages to touch on the entire lifecycle of medicines and work to ensure cross-border collaboration.
Watch Emilia Valbum and Karel Lannoo discuss the role of HERA and how businesses can support it.
Related items
:focal())
News
27 Oct 2025
Advancing EU health policy through competitiveness and innovation
On Monday, 27 October, AmCham EU met with Lorena Boix-Alonso, Deputy Director-General, Directorate-General for Health and Food Safety, European Commission, for an exchange on the role of health policy in strengthening the EU’s competitiveness. The discussion focused on how to foster innovation while ensuring patient safety, as well as ways to streamline the legislative framework to improve efficiency and uphold high standards of care. AmCham EU highlighted the importance of evidence-based, future-proof regulation that supports a resilient health system and drives innovation. Continued dialogue is essential to advancing shared goals for Europe’s health agenda.
:focal())
News
9 Oct 2025
Advancing European healthcare in Strasbourg
From Tuesday, 7 to Wednesday, 8 October, AmCham EU travelled to the European Parliament in Strasbourg, France to engage with MEPs on the future of EU health policy. In meetings with over a dozen policymakers, members underscored the importance of a competitive, innovation-driven life sciences sector that ensures timely patient access to medicines and technologies. The discussions also covered the General Pharmaceutical Legislation, the Medical Devices Regulation, the Critical Medicines Act and the upcoming Biotech Act. The delegation called for evidence-based, proportionate policies that promote regulatory coherence and support Europe’s global leadership in health innovation.
News
4 May 2025
How the Critical Medicines Act will strengthen Europe’s life sciences sector
On Wednesday, 30 April, Thibaut L'Ortye, Senior Director of Public Affairs, AmCham EU, joined a panel discussion on the Critical Medicines Act (CMA). Hosted by the European Policy Centre, Mr L'Ortye underlined the need for open and resilient supply chains to ensure continued access to medicines. He also highlighted the CMA’s potential to strengthen Europe's competitiveness and improve patient access. Avoiding protectionist measures and aligning the CMA with the EU’s wider simplification efforts is essential to attract investment into the Single Market. The discussion highlighted the importance of public-private collaboration to build a more competitive life sciences sector in the EU.
Policy priorities
Insights and advocacy driving Europe’s policy agenda. Our priorities support growth, innovation and a stronger transatlantic economy.
Membership
Connecting business and policymakers to strengthen the voice of American companies in Europe.